Skip to main content
Erschienen in: Diabetologia 1/2004

01.01.2004 | Article

Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes

verfasst von: S. X. Zhang, J. Sima, C. Shao, J. Fant, Y. Chen, B. Rohrer, G. Gao, J-x. Ma, MD PhD

Erschienen in: Diabetologia | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Retinal vascular leakage is an early pathological feature in diabetic retinopathy and can lead to macular oedema and loss of vision. Previously we have shown that plasminogen kringle 5 (K5), an angiogenic inhibitor, inhibits retinal neovascularisation in the rat model of oxygen-induced retinopathy (OIR). The purpose of this study was to examine the effect of K5 on vascular leakage in the retina.

Methods

Neonatal rats were exposed to hyperoxia to induce OIR. Diabetes was induced in adult rats by injecting streptozotocin. Vascular permeability was measured by Evans blue method. Expression of vascular endothelial growth factor (VEGF) was evaluated using immunohistochemistry and western blot analysis.

Results

Rats with OIR and diabetes showed abnormal vascular hyperpermeability in the retina and iris. Intravitreal injection of K5, reduced vascular permeability in both animal models, but did not affect permeability in normal rats. K5 reduced vascular permeability at doses substantially lower than that required for inhibition of retinal neovascularisation. The K5-induced reduction in vascular permeability correlated with its down-regulation of VEGF expression in the retina. Moreover, K5 inhibited IGF-1-induced hyperpermeability, which is known to arise through up-regulation of endogenous VEGF expression. However, K5 had no effect on the hyperpermeability induced by injection of exogenous VEGF.

Conclusions/interpretation

Very low doses of K5 reduce pathological vascular leakage in the retina. K5 thus has therapeutic potential in the treatment of diabetic macular oedema. This effect can be ascribed, at least in part, to the down-regulation of endogenous VEGF expression.
Literatur
1.
Zurück zum Zitat Ciulla TA, Danis RP, Harris A (1998) Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 43:134–146 Ciulla TA, Danis RP, Harris A (1998) Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 43:134–146
2.
Zurück zum Zitat Antonetti DA, Lieth E, Barber AJ, Gardner TW (1999) Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 14:240–248PubMed Antonetti DA, Lieth E, Barber AJ, Gardner TW (1999) Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 14:240–248PubMed
4.
Zurück zum Zitat Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BM, Leite E (1985) Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes 34:53–59PubMed Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BM, Leite E (1985) Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes 34:53–59PubMed
5.
Zurück zum Zitat Yoshida A, Ishiko S, Kojima M, Ogasawara H (1993) Permeability of the blood-ocular barrier in adolescent and adult diabetic patients. Br J Ophthalmol 77:158–161PubMed Yoshida A, Ishiko S, Kojima M, Ogasawara H (1993) Permeability of the blood-ocular barrier in adolescent and adult diabetic patients. Br J Ophthalmol 77:158–161PubMed
6.
Zurück zum Zitat Moss SE, Klein R, Klein BE (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998–1003PubMed Moss SE, Klein R, Klein BE (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:998–1003PubMed
7.
Zurück zum Zitat Qaum T, Xu Q, Joussen AM et al. (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408–2413PubMed Qaum T, Xu Q, Joussen AM et al. (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408–2413PubMed
8.
Zurück zum Zitat Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659 Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659
9.
Zurück zum Zitat Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed
10.
Zurück zum Zitat Aiello LP, Wong JS (2000) Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77:S113–S119CrossRefPubMed Aiello LP, Wong JS (2000) Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77:S113–S119CrossRefPubMed
11.
Zurück zum Zitat Aiello LP (1997) Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29:354–362PubMed Aiello LP (1997) Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29:354–362PubMed
12.
Zurück zum Zitat Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819–825PubMed Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819–825PubMed
13.
Zurück zum Zitat Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401–406PubMed Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401–406PubMed
14.
Zurück zum Zitat Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M (1997) Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272:22924–22928CrossRefPubMed Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M (1997) Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272:22924–22928CrossRefPubMed
15.
Zurück zum Zitat Chang Y, Mochalkin I, McCance SG, Cheng B, Tulinsky A, Castellino FJ (1998) Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry 37:3258–3271CrossRefPubMed Chang Y, Mochalkin I, McCance SG, Cheng B, Tulinsky A, Castellino FJ (1998) Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry 37:3258–3271CrossRefPubMed
16.
Zurück zum Zitat Gao G, Li Y, Gee S et al. (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277:9492–9497CrossRefPubMed Gao G, Li Y, Gee S et al. (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277:9492–9497CrossRefPubMed
17.
Zurück zum Zitat Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX (2001) Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44:757–765CrossRefPubMed Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX (2001) Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44:757–765CrossRefPubMed
18.
Zurück zum Zitat Smith LE, Wesolowski E, McLellan A et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111 Smith LE, Wesolowski E, McLellan A et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111
19.
Zurück zum Zitat Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX (2002) Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 51:1218–1225PubMed Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX (2002) Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 51:1218–1225PubMed
20.
Zurück zum Zitat Xu Q, Qaum T, Adamis AP (2001) Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789–794 Xu Q, Qaum T, Adamis AP (2001) Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789–794
21.
Zurück zum Zitat Radius RL, Anderson DR (1980) Distribution of albumin in the normal monkey eye as revealed by Evans blue fluorescence microscopy. Invest Ophthalmol Vis Sci 19:238–243 Radius RL, Anderson DR (1980) Distribution of albumin in the normal monkey eye as revealed by Evans blue fluorescence microscopy. Invest Ophthalmol Vis Sci 19:238–243
22.
Zurück zum Zitat Rohrer B, Stell WK (1995) Localization of putative dopamine D2-like receptors in the chick retina, using in situ hybridization and immunocytochemistry. Brain Res 695:110–116PubMed Rohrer B, Stell WK (1995) Localization of putative dopamine D2-like receptors in the chick retina, using in situ hybridization and immunocytochemistry. Brain Res 695:110–116PubMed
23.
Zurück zum Zitat Bresnick GH (1986) Diabetic macular edema. A review. Ophthalmology 93:989–997PubMed Bresnick GH (1986) Diabetic macular edema. A review. Ophthalmology 93:989–997PubMed
24.
Zurück zum Zitat Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW (1999) Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 77:170–175PubMed Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW (1999) Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 77:170–175PubMed
25.
Zurück zum Zitat Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270–276CrossRefPubMed Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270–276CrossRefPubMed
26.
Zurück zum Zitat Petrova TV, Makinen T, Alitalo K (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253:117–130CrossRefPubMed Petrova TV, Makinen T, Alitalo K (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253:117–130CrossRefPubMed
27.
Zurück zum Zitat Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333–346PubMed Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333–346PubMed
28.
Zurück zum Zitat Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905–909PubMed Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905–909PubMed
29.
Zurück zum Zitat Senger DR, Connolly DT, Water L van de, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774–1778PubMed Senger DR, Connolly DT, Water L van de, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774–1778PubMed
30.
Zurück zum Zitat Adamis AP, Miller JW, Bernal MT et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed Adamis AP, Miller JW, Bernal MT et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed
31.
Zurück zum Zitat Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMed Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMed
32.
Zurück zum Zitat Pe’er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72:638–645PubMed Pe’er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72:638–645PubMed
33.
Zurück zum Zitat Aiello LP, George DJ, Cahill MT et al. (2002) Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109:1745–1751CrossRefPubMed Aiello LP, George DJ, Cahill MT et al. (2002) Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109:1745–1751CrossRefPubMed
34.
Zurück zum Zitat Ryan AM, Eppler DB, Hagler KE et al. (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78–86PubMed Ryan AM, Eppler DB, Hagler KE et al. (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78–86PubMed
35.
Zurück zum Zitat Via LE, Gore-Langton RE, Pluda JM (2000) Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology (Huntington) 14:1321–1323 Via LE, Gore-Langton RE, Pluda JM (2000) Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology (Huntington) 14:1321–1323
36.
Zurück zum Zitat Engerman RL (1976) Animal models of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 81:OP710–OP715 Engerman RL (1976) Animal models of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 81:OP710–OP715
37.
Zurück zum Zitat Miyamoto K, Khosrof S, Bursell SE et al. (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836–10841PubMed Miyamoto K, Khosrof S, Bursell SE et al. (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836–10841PubMed
38.
Zurück zum Zitat Aiello LP, Bursell SE, Clermont A et al. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46:1473–1480PubMed Aiello LP, Bursell SE, Clermont A et al. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46:1473–1480PubMed
Metadaten
Titel
Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes
verfasst von
S. X. Zhang
J. Sima
C. Shao
J. Fant
Y. Chen
B. Rohrer
G. Gao
J-x. Ma, MD PhD
Publikationsdatum
01.01.2004
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 1/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1276-4

Weitere Artikel der Ausgabe 1/2004

Diabetologia 1/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.